At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Ipilimumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus
In Brief
A Phase 2 clinical trial evaluating Ipilimumab, Laboratory Biomarker Analysis, and 1 other intervention for Metastatic Leiomyosarcoma and 2 related conditions. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
This phase II trial studies how well nivolumab alone or in combination with ipilimumab works in treating patients with uterine cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionSep 2018
Study CompletionJan 2021
TodayJul 2026
First PostedApr 28, 2015
Enrollment StartMay 19, 2015
Primary CompletionSep 20, 2018
Study CompletionJan 28, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.2 years ago
Interventions
Ipilimumabbiological
Given IV
Laboratory Biomarker Analysisother
Correlative studies
Nivolumabbiological
Given IV